[{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Tsinghua University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"BRII-196","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Brii Biosciences \/ Tsinghua University","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Tsinghua University"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"BRII-196","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Brii Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"VBI Vaccines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ VBI Vaccines","highestDevelopmentStatusID":"7","companyTruncated":"Brii Biosciences \/ VBI Vaccines"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BRII-196","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Amubarvimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Sinopharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Sinopharm","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosciences \/ Sinopharm"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"VIR-2218","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"TSB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brii Biosciences \/ TSB Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosciences \/ TSB Therapeutics"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Islatravir Prodrug","moa":"NRTI","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BRII-297","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Qpex Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"BRII-693","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brii Biosciences \/ Qpex Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Brii Biosciences \/ Qpex Biopharma"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0.44,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.44,"dosageForm":"Injectable\/Injection","sponsorNew":"Brii Biosciences \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Brii Biosciences"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"VBI Vaccines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Brii Biosciences \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Brii Biosciences"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"BRII-179","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Brii Biosciences \/ Brii Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Brii Biosciences"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rilpivirine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Brii Biosciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Brii Biosciences \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Brii Biosciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the acquisition, Brii will get access to focus on the development of VBI-2601 (BRII-179), a protein-based HBV immunotherapeutic candidate intended for the treatment of chronic HBV infection.

                          Brand Name : VBI-2601

                          Molecule Type : Vaccine

                          Upfront Cash : $10.0 million

                          February 13, 2024

                          Lead Product(s) : BRII-179,Elebsiran

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : VBI Vaccines

                          Deal Size : $33.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity.

                          Brand Name : VBI-2601

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 06, 2023

                          Lead Product(s) : BRII-179,VIR-2218

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : VBI Vaccines

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the collaboration, Brii Bio expanded its exclusive license to VBI-2601 (BRII-179), VBI’s HBV immunotherapeutic candidate, to global rights and acquired an exclusive license for PreHevbri, VBI’s 3-antigen hepatitis B vaccine, in the Asia Pacific...

                          Brand Name : VBI-2601

                          Molecule Type : Vaccine

                          Upfront Cash : $15.0 million

                          July 05, 2023

                          Lead Product(s) : BRII-179

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : VBI Vaccines

                          Deal Size : $437.0 million

                          Deal Type : Expanded Collaboration

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Brii Bio will acquire exclusive global rights for the development and commercialization of QPX9003 (BRII-693), a novel synthetic lipopeptide in development for the treatment of MDR/XDR gram-negative bacterial infections, to expand from its existing right...

                          Brand Name : QPX9003

                          Molecule Type : Peptide

                          Upfront Cash : $24.0 million

                          June 25, 2023

                          Lead Product(s) : BRII-693

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Qpex Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BRII-297 is a gamma-aminobutyric acid A receptor positive allosteric modulator and first-of-its-kind long-acting injectable therapeutic candidate in development for the treatment of various anxiety and depressive disorders.

                          Brand Name : BRII-297

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 31, 2023

                          Lead Product(s) : BRII-297

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BRII-732/BRII-778 combination is currently in Phase 1 development in the U.S. as therapy for human immunodeficiency virus infection that can be administered on weekly basis potentially preferable choice for patients currently receiving once-daily treatme...

                          Brand Name : BRII-732

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 19, 2022

                          Lead Product(s) : Islatravir Prodrug,Rilpivirine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BRII-778 (rilpivirine), a modified-release Oral Formulation is being evaluated in the early-stage clinical trials studies for the treatment of patients suffering from HIV-infections.

                          Brand Name : BRII-778

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 19, 2022

                          Lead Product(s) : Rilpivirine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Independent lab results demonstrate that the BRII-196 (amubarvimab/romlusevimab) combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date.

                          Brand Name : BRII-196

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 26, 2022

                          Lead Product(s) : Amubarvimab,Romlusevimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BRII-196 (amubarvimab) and romlusevimab are non-competing SARS-CoV-2 mAB derived from convalesced COVID-19 patients, have been specifically engineered to reduce risk of antibody-dependent enhancement and prolong plasma half-lives for potentially more dur...

                          Brand Name : BRII-196

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 07, 2022

                          Lead Product(s) : Amubarvimab,Romlusevimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : TSB Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Studies conducted by independent labs demonstrated the BRII-196 (amubarvimab) in combination with romlusevimab retains neutralizing activity against COVID-19 Omicron variant.

                          Brand Name : BRII-196

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 09, 2022

                          Lead Product(s) : Amubarvimab,Romlusevimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank